All of the shares are being offered by XenoPort. Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. are acting as joint book-runners for the offering. A copy of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from Morgan Stanley & Co. Incorporated, Attn: Prospectus Department, 180 Varick Street, New York, New York 10014 (Email prospectus@morganstanley.com) or Goldman, Sachs & Co., Attn: Registration Department, 85 Broad Street, 20th Floor, New York, New York, 10004 (Telephone number 1-866-471-2526 or prospectus-ny@ny.email.gs.com).

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of, these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate, XP13512, in collaboration with Astellas Pharma Inc. and GlaxoSmithKline. The Food and Drug Administration is currently reviewing the new drug application for this product candidate as a potential treatment for moderate-to-severe primary restless legs syndrome. XenoPort's product candidates are also being studied for the potential treatment of gastroesophageal reflux disease, migraine headaches, neuropathic pain, spasticity related to spinal cord injury, acute back spasms and Parkinson's disease.

XenoPort is a registered trademark.

XNPT2F

A service of YellowBrix, Inc.